Pharmaceutical

Kezar and Everest enter lupus nephritis therapy development deal

Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.

Sep 21, 2023 - 20:00
Kezar and Everest enter lupus nephritis therapy development deal
Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.
Read the original article

Tags:

Previous Article

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with ana...

Next Article

FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation

STAT+: ‘It was my call’: Stanford president defends dec...

Apr 11, 2023

Sandoz partners with Samsung Bioepis to license Stelara biosimilar

Sandoz partners with Samsung Bioepis to license Stelara...

Sep 11, 2023

NImmune and BioTherapeutics partner on precision medicine development

NImmune and BioTherapeutics partner on precision medici...

Sep 8, 2024